356 Baseline PD-L1 expression and tumor immune infiltration is associated with clinical response in patients with r/r DLBCL treated with DPX-Survivac, low-dose cyclophosphamide and...

by Neil Berinstein, Isabelle Bence-Bruckler, Nick Forward, Pierre Laneuville, Joy Mangel, Douglas Stewart, Irina Amitai, Gail Klein, Nancy Pennell, Iran Rashedi, Kim Roos, Yogesh Bramhecha, Rebekah Conlon
Published 2020-11-01